Earnings ·
Coya Therapeutics reported financial results for the quarter ended June 30, 2026
COYACoya Therapeutics, Inc.
Coya Therapeutics reported financial results for the quarter ended June 30, 2026. The company held $43.2 million in cash and incurred a net loss of $6.6 million, with research and development expenses rising to $5.0 million due to clinical trial advancements. General and administrative costs decreased by $0.6 million to $2.3 million. The firm raised approximately $10.95 million through an ATM offering program. Clinically, Coya received FDA Fast Track Designation for its lead candidate COYA 302 in ALS, initiated a Phase 2 study in frontotemporal dementia (FTD), and plans to complete ALSTARS trial enrollment by the end of 2026 with top-line data expected in Q1 2027. Coya Therapeutics is a clinical-stage biotechnology company developing biologics intended to enhance T-cell function in patients with neurodegenerative disorders.